Fierce BioBiotech
Biogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibody
Summary
Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building on an existing partnership with local drugmaker TJ Biopharma.
Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building on an existing partnership with local drugmaker TJ Biopharma.